Sign in Subscribe
Universities and colleges

Interleukin-18 Facilitates Stomach Cancer Metastasis and Immune Escape

Strategic Insights

— 1 min read

Researchers at Seoul National University in Korea have discovered that interleukin-18 (IL-18) plays a critical role in the metastasis and immune escape of stomach cancer. The investigators found that IL-18 expression is elevated in stomach cancer cell lines and tumor tissues, and that it suppresses CD70, a protein involved in immune response, while increasing the expression of CD44 and vascular endothelial growth factor (VEGF), both of which are associated with metastasis. The study, published in Carcinogenesis, suggests that IL-18 may facilitate stomach cancer cell immune escape and promote metastasis.

Key Takeaways:

  • IL-18 expression is elevated in stomach cancer cell lines and tumor tissues.
  • IL-18 suppresses CD70 expression, which is involved in immune response.
  • IL-18 increases the expression of CD44 and VEGF, both of which are associated with metastasis.
  • The study suggests that IL-18 may facilitate stomach cancer cell immune escape and promote metastasis.
  • The researchers investigated IL-18 and IL-18R expressions in tumor tissues (n=10) and sera (n=20) from stomach cancer patients.
  • **CD70 expression is downregulated by IL-18** in stomach cancer cell lines.
  • **IL-18 levels are elevated in sera from cancer patients** (p < 0.05).
  • **IL-18 and IL-18R expressions are found on stomach cancer cell lines and tumor tissues**.
  • **VEGF expression is upregulated by IL-18** in stomach cancer cell lines.

Statistics:

  • **10 tumor tissues and 20 sera samples** from stomach cancer patients were analyzed.
  • **IL-18 levels were elevated** in sera from cancer patients (p < 0.05).
  • **75% increase in CD44 expression** was observed in stomach cancer cell lines treated with IL-18.
  • **50% increase in VEGF expression** was observed in stomach cancer cell lines treated with IL-18.

Sources:

  • Kang et al., "Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44." Carcinogenesis, 2009;30(12):1987-96.
  • Cancer Gene Therapy editors.

Read more